Greenland Mines Ltd (NasdaqCM: GRML)
Health Care · Biotechnology · US
$0.20
-0.30% today · -73.1% 1Y
Greenland Mines Ltd (NasdaqCM: GRML) operates in the Biotechnology industry within the Health Care sector. The company is valued at $32.20M and employs 5 people.
Over the last twelve months the share price has lost 73.1%, trading between 0.16 and 0.79.
Tweenvest scores Greenland Mines Ltd across four factors: quality 26/100. Its strongest factor is quality.
GRML price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $32.20M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.25
- Dividend yield
- —
- Beta (5Y)
- 2.56
- 52-week high
- $0.79
- 52-week low
- $0.16
- Avg volume (3M)
- —
- Shares outstanding
- 158.85M
- Employees
- 5
- Next earnings
- —
About Greenland Mines Ltd
Greenland Mines Ltd. (GRML) focuses on developing innovative therapeutic solutions to combat neurodegenerative diseases. The company's primary treatment modalities involve cutting-edge cell and gene therapies. Joseph Sinkule founded this enterprise on August 2, 2004, and its corporate operations are based in Omaha, Nebraska.
- ISIN
- US49876K2024
- Listed since
- Apr 29, 2022
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.96 | +0.06% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €894.20 | +1.71% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.